{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:18:23Z","timestamp":1771993103975,"version":"3.50.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T00:00:00Z","timestamp":1361232000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1038\/nrcardio.2013.13","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T12:05:21Z","timestamp":1361275521000},"page":"248-260","source":"Crossref","is-referenced-by-count":114,"title":["New concepts in the design of drug-eluting coronary stents"],"prefix":"10.1038","volume":"10","author":[{"given":"Scot","family":"Garg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Bourantas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,19]]},"reference":[{"key":"BFnrcardio201313_CR1","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","volume":"346","author":"MC Morice","year":"2002","unstructured":"Morice, M. C. et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346, 1773\u20131780 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-148-3-200802050-00199","volume":"148","author":"A Jeremias","year":"2008","unstructured":"Jeremias, A. & Kirtane, A. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann. Intern. Med. 148, 234\u2013238 (2008).","journal-title":"Ann. Intern. Med."},{"key":"BFnrcardio201313_CR3","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/CIRCULATIONAHA.106.666800","volume":"115","author":"E Camenzind","year":"2007","unstructured":"Camenzind, E., Steg, P. G. & Wijns, W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115, 1440\u20131455 (2007).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR4","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/eurheartj\/ehl282","volume":"27","author":"AJ Nordmann","year":"2006","unstructured":"Nordmann, A. J., Briel, M. & Bucher, H. C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur. Heart J. 27, 2784\u20132814 (2006).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201313_CR5","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa067722","volume":"356","author":"B Lagerqvist","year":"2007","unstructured":"Lagerqvist, B. et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 356, 1009\u20131019 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR6","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jacc.2006.10.026","volume":"48","author":"M Pfisterer","year":"2006","unstructured":"Pfisterer, M. et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48, 2584\u20132591 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMp068304","volume":"356","author":"A Farb","year":"2007","unstructured":"Farb, A. & Boam, A. B. Stent thrombosis redux\u2014the FDA perspective. N. Engl. J. Med. 356, 984\u2013987 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR8","first-page":"152","volume":"30","author":"J Daemen","year":"2009","unstructured":"Daemen, J. et al. ESC forum on drug-eluting stents. European Heart House, Nice, 27\u201328 September 2007. Eur. Heart J. 30, 152\u2013161 (2009).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201313_CR9","first-page":"147","volume":"1","author":"PW Serruys","year":"2005","unstructured":"Serruys, P. W. et al. Arterial Revascularisation Therapies Study Part II\u2014Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroIntervention 1, 147\u2013156 (2005).","journal-title":"EuroIntervention"},{"key":"BFnrcardio201313_CR10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/01.CIR.0000047700.58683.A1","volume":"107","author":"E Grube","year":"2003","unstructured":"Grube, E. et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107, 38\u201342 (2003).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR11","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa0804626","volume":"360","author":"PW Serruys","year":"2009","unstructured":"Serruys, P. W. et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 360, 961\u2013972 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR12","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/CIRCULATIONAHA.105.562421","volume":"112","author":"M Sabat\u00e9","year":"2005","unstructured":"Sabat\u00e9, M. et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112, 2175\u20132183 (2005).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jacc.2007.10.035","volume":"51","author":"AJ Kirtane","year":"2008","unstructured":"Kirtane, A. J. et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J. Am. Coll. Cardiol. 51, 708\u2013715 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa062006","volume":"355","author":"C Spaulding","year":"2006","unstructured":"Spaulding, C. et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N. Engl. J. Med. 355, 1093\u20131104 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR15","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa062598","volume":"355","author":"GJ Laarman","year":"2006","unstructured":"Laarman, G. J. et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N. Engl. J. Med. 355, 1105\u20131113 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacc.2010.06.007","volume":"56","author":"S Garg","year":"2010","unstructured":"Garg, S. & Serruys, P. W. Coronary stents: current status. J. Am. Coll. Cardiol. 56, S1\u2013S42 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR17","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2010.06.008","volume":"56","author":"S Garg","year":"2010","unstructured":"Garg, S. & Serruys, P. W. Coronary stents: looking forward. J. Am. Coll. Cardiol. 56, S43\u2013S78 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR18","first-page":"51","volume-title":"Percutaneous Interventional Cardiovascular Medicine","author":"S Garg","year":"2012","unstructured":"Garg, S., Raber, L., Serruys, P. W. & Windecker, S. in Percutaneous Interventional Cardiovascular Medicine Part III Ch. 3 (Eds Eeckhout, E., Serruys, P. W., Wijns, W., Vahanian, A., van Sambeek, M.) 51\u2013144 (Europa Edition Publishing, Paris, 2012)."},{"key":"BFnrcardio201313_CR19","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(07)61444-5","volume":"370","author":"C Stettler","year":"2007","unstructured":"Stettler, C. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370, 937\u2013948 (2007).","journal-title":"Lancet"},{"key":"BFnrcardio201313_CR20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1586\/erc.09.138","volume":"8","author":"S Garg","year":"2010","unstructured":"Garg, S. & Serruys, P. W. Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Rev. Cardiovasc. Ther. 8, 449\u2013470 (2010).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"BFnrcardio201313_CR21","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/eurheartj\/ehm402","volume":"28","author":"A Kastrati","year":"2007","unstructured":"Kastrati, A. et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur. Heart J. 28, 2706\u20132713 (2007).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201313_CR22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4244\/EIJV3I3A70","volume":"3","author":"J Daemen","year":"2007","unstructured":"Daemen, J. et al. A pooled safety analysis of data comparing paclitaxel-eluting stents with bare-metal stents. EuroIntervention 3, 392\u2013399 (2007).","journal-title":"EuroIntervention"},{"key":"BFnrcardio201313_CR23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa066633","volume":"356","author":"C Spaulding","year":"2007","unstructured":"Spaulding, C., Daemen, J., Boersma, E., Cutlip, D. E. & Serruys, P. W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356, 989\u2013997 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","volume":"356","author":"L Mauri","year":"2007","unstructured":"Mauri, L. et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 356, 1020\u20131029 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR25","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa067193","volume":"356","author":"GW Stone","year":"2007","unstructured":"Stone, G. W. et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356, 998\u20131008 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR26","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/CIRCULATIONAHA.108.826479","volume":"119","author":"AJ Kirtane","year":"2009","unstructured":"Kirtane, A. J. et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 119, 3198\u20133206 (2009).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.amjcard.2008.03.055","volume":"102","author":"TL Pinto Slottow","year":"2008","unstructured":"Pinto Slottow, T. L. et al. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am. J. Cardiol. 102, 298\u2013303 (2008).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio201313_CR28","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4244\/EIJV5I4A79","volume":"5","author":"SK James","year":"2009","unstructured":"James, S. K., Wallentin, L. & Lagerqvist, B. for the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) study group. The SCAAR-scare in perspective. EuroIntervention 5, 501\u2013504 (2009).","journal-title":"EuroIntervention"},{"key":"BFnrcardio201313_CR29","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jacc.2008.07.006","volume":"52","author":"P Wenaweser","year":"2008","unstructured":"Wenaweser, P. et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol. 52, 1134\u20131140 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM199101033240103","volume":"324","author":"PW Serruys","year":"1991","unstructured":"Serruys, P. W. et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N. Engl. J. Med. 324, 13\u201317 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR31","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2009.11.049","volume":"55","author":"PW Serruys","year":"2010","unstructured":"Serruys, P. W. et al. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J. Am. Coll. Cardiol. 55, 1093\u20131101 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR32","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jacc.2010.07.016","volume":"56","author":"DR Holmes Jr.","year":"2010","unstructured":"Holmes, D. R. Jr. et al. Stent thrombosis. J. Am. Coll. Cardiol. 56, 1357\u20131365 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR33","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","volume":"53","author":"JW van Werkum","year":"2009","unstructured":"van Werkum, J. W. et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J. Am. Coll. Cardiol. 53, 1399\u20131409 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","volume":"48","author":"M Joner","year":"2006","unstructured":"Joner, M. et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48, 193\u2013202 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR35","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jacc.2011.01.011","volume":"57","author":"G Nakazawa","year":"2011","unstructured":"Nakazawa, G. et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J. Am. Coll. Cardiol. 57, 1314\u20131322 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jcin.2009.10.031","volume":"3","author":"M Hara","year":"2010","unstructured":"Hara, M. et al. Difference of neointimal formational pattern and incidence of thrombus formation among 3 kinds of stents: an angioscopic study. JACC Cardiovasc. Interv. 3, 215\u2013220 (2010).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio201313_CR37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1056\/NEJM199602293340903","volume":"334","author":"T Kimura","year":"1996","unstructured":"Kimura, T. et al. Three-year follow-up after implantation of metallic coronary-artery stents. N. Engl. J. Med. 334, 561\u2013566 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR38","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1161\/CIRCULATIONAHA.110.004762","volume":"123","author":"L Raber","year":"2011","unstructured":"Raber, L. et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 123, 2819\u20132828 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR39","unstructured":"US Department of Health & Human Services. FDA. Approval document for Cypher sirolimus eluting stent [online] , (2004)."},{"key":"BFnrcardio201313_CR40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcin.2008.06.005","volume":"1","author":"BR Brodie","year":"2008","unstructured":"Brodie, B. R. et al. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group. JACC Cardiovasc. Interv. 1, 405\u2013414 (2008).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio201313_CR41","first-page":"405","volume":"2","author":"PW Serruys","year":"2007","unstructured":"Serruys, P. W. FDA panel, 7 and 8 December 2006\u2014The impact on our practice and research. EuroIntervention 2, 405\u2013407 (2007).","journal-title":"EuroIntervention"},{"key":"BFnrcardio201313_CR42","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jacc.2007.06.047","volume":"50","author":"A Schomig","year":"2007","unstructured":"Schomig, A. et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J. Am. Coll. Cardiol. 50, 1373\u20131380 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR43","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1161\/CIRCINTERVENTIONS.111.963256","volume":"4","author":"A de Waha","year":"2011","unstructured":"de Waha, A. et al. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circ. Cardiovasc. Interv. 4, 371\u2013377 (2011).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"BFnrcardio201313_CR44","doi-asserted-by":"publisher","unstructured":"Fan, J. et al. Efficacy and safety of zotarolimus-eluting stents compared with sirolimus-eluting stents in patients undergoing percutaneous coronary interventions\u2014a meta-analysis of randomized controlled trials. Int. J. Cardiol. http:\/\/dx.doi.org\/10.1016\/j.ijcard.2012.05.105 .","DOI":"10.1016\/j.ijcard.2012.05.105"},{"key":"BFnrcardio201313_CR45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jacc.2008.04.030","volume":"52","author":"M Joner","year":"2008","unstructured":"Joner, M. et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol. 52, 333\u2013342 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR46","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/CIRCULATIONAHA.109.854398","volume":"120","author":"S Cook","year":"2009","unstructured":"Cook, S. et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 120, 391\u2013399 (2009).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR47","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1004130","volume":"363","author":"PW Serruys","year":"2010","unstructured":"Serruys, P. W. et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N. Engl. J. Med. 363, 136\u2013146 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(09)62127-9","volume":"375","author":"E Kedhi","year":"2010","unstructured":"Kedhi, E. et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 375, 201\u2013209 (2010).","journal-title":"Lancet"},{"key":"BFnrcardio201313_CR49","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1161\/CIRCULATIONAHA.111.031070","volume":"124","author":"GW Stone","year":"2011","unstructured":"Stone, G. W. et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 124, 893\u2013900 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR50","doi-asserted-by":"crossref","first-page":"126369","DOI":"10.1155\/2012\/126369","volume":"2012","author":"A Alazzoni","year":"2012","unstructured":"Alazzoni, A., Al-Saleh, A. & Jolly, S. S. Everolimus-eluting versus paclitaxel-eluting stents in percutaneous coronary intervention: meta-analysis of randomized trials. Thrombosis 2012, 126369 (2012).","journal-title":"Thrombosis"},{"key":"BFnrcardio201313_CR51","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1136\/heartjnl-2012-302519","volume":"98","author":"S Cassese","year":"2012","unstructured":"Cassese, S. et al. Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparison. Heart 98, 1632\u20131640 (2012).","journal-title":"Heart"},{"key":"BFnrcardio201313_CR52","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/ccd.22206","volume":"74","author":"IT Meredith","year":"2009","unstructured":"Meredith, I. T. et al. Five-year clinical follow-up after implantation of the Endeavor zotarolimus-eluting stent: ENDEAVOR I, first-in-human study. Catheter. Cardiovasc. Interv. 74, 989\u2013995 (2009).","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"BFnrcardio201313_CR53","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ccd.22428","volume":"75","author":"M Wiemer","year":"2010","unstructured":"Wiemer, M. et al. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT FIRST trial. Catheter. Cardiovasc. Interv. 75, 997\u20131003 (2010).","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"BFnrcardio201313_CR54","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jacc.2009.08.067","volume":"55","author":"MB Leon","year":"2010","unstructured":"Leon, M. B. et al. A randomised comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS Paclitaxel-eluting stent in de novo native coronary lesions: 12-month outcomes from the ENDEAVOR IV trial. J. Am. Coll. Cardiol. 55, 543\u2013554 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR55","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.jacc.2006.08.035","volume":"48","author":"DE Kandzari","year":"2006","unstructured":"Kandzari, D. E. et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol. 48, 2440\u20132447 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR56","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jcin.2010.07.008","volume":"3","author":"MB Leon","year":"2010","unstructured":"Leon, M. B. et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. JACC Cardiovasc. Interv. 3, 1043\u20131050 (2010).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio201313_CR57","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0140-6736(12)61336-1","volume":"380","author":"E Camenzind","year":"2012","unstructured":"Camenzind, E. et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 380, 1396\u20131405 (2012).","journal-title":"Lancet"},{"key":"BFnrcardio201313_CR58","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jacc.2012.01.008","volume":"59","author":"C von Birgelen","year":"2012","unstructured":"von Birgelen, C. et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J. Am. Coll. Cardiol. 59, 1350\u20131361 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR59","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/CIRCINTERVENTIONS.111.965673","volume":"5","author":"JM Ahn","year":"2012","unstructured":"Ahn, J. M. et al. Comparison of Resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial. Circ. Cardiovasc. Interv. 5, 633\u2013640 (2012).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"BFnrcardio201313_CR60","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","volume":"379","author":"T Palmerini","year":"2012","unstructured":"Palmerini, T. et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 379, 1393\u20131402 (2012).","journal-title":"Lancet"},{"key":"BFnrcardio201313_CR61","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","volume":"123","author":"K Kolandaivelu","year":"2011","unstructured":"Kolandaivelu, K. et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123, 1400\u20131409 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR62","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","volume":"125","author":"S Bangalore","year":"2012","unstructured":"Bangalore, S. et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117, 762 patient-years of follow-up from randomized trials. Circulation 125, 2873\u20132891 (2012).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR63","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCINTERVENTIONS.111.967083","volume":"5","author":"T Palmerini","year":"2012","unstructured":"Palmerini, T. et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ. Cardiovasc. Interv. 5, 357\u2013364 (2012).","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"Suppl. F","key":"BFnrcardio201313_CR64","doi-asserted-by":"crossref","first-page":"F36","DOI":"10.4244\/EIJV5IFA6","volume":"5","author":"R Waksman","year":"2009","unstructured":"Waksman, R. & Pakala, R. Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent. EuroIntervention 5 (Suppl. F), F36\u2013F42 (2009).","journal-title":"EuroIntervention"},{"key":"BFnrcardio201313_CR65","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(08)61244-1","volume":"372","author":"S Windecker","year":"2008","unstructured":"Windecker, S. et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372, 1163\u20131173 (2008).","journal-title":"Lancet"},{"key":"BFnrcardio201313_CR66","unstructured":"Serruys, P. W. Five-year outcomes from the LEADERS trial. Presented at 24th Transcatheter Cardiovascular Therapeutics 2012."},{"key":"BFnrcardio201313_CR67","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","volume":"33","author":"GG Stefanini","year":"2012","unstructured":"Stefanini, G. G. et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur. Heart J. 33, 1214\u20131222 (2012).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201313_CR68","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/eurheartj\/ehp480","volume":"31","author":"P Barlis","year":"2010","unstructured":"Barlis, P. et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur. Heart J. 31, 165\u2013176 (2010).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201313_CR69","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ahj.2011.09.005","volume":"162","author":"JL Gutierr\u00e9z-Chico","year":"2011","unstructured":"Gutierr\u00e9z-Chico, J. L. et al. Long-term tissue coverage of a biodegradable polylactide polymer-coated biolimus-eluting stent: comparative sequential assessment with optical coherence tomography until complete resorption of the polymer. Am. Heart J. 162, 922\u2013931 (2011).","journal-title":"Am. Heart J."},{"key":"BFnrcardio201313_CR70","unstructured":"Smits, P. Primary endpoint results from the COMPARE II trial: a large scale, multicentre, prospective randomised comparison between the everolimus-eluting stent with a durable polymer and the biolimus-eluting stent with an abluminal biodegradable polymer in a real-life setting. Presented at EuroPCR 2012."},{"key":"BFnrcardio201313_CR71","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa021007","volume":"348","author":"SJ Park","year":"2003","unstructured":"Park, S. J. et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N. Engl. J. Med. 348, 1537\u20131545 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201313_CR72","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCINTERVENTIONS.109.877522","volume":"3","author":"N Tada","year":"2010","unstructured":"Tada, N. et al. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ. Cardiovasc. Interv. 3, 174\u2013183 (2010).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"BFnrcardio201313_CR73","unstructured":"Grube, E. Biofreedom: polymer-free drug-eluting stent\u2014preclinical results and first-in-man trial status. Presented at EuroPCR 2009."},{"key":"BFnrcardio201313_CR74","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jcin.2008.07.003","volume":"1","author":"JR Costa Jr.","year":"2008","unstructured":"Costa, J. R. Jr. et al. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system. JACC Cardiovasc. Interv. 1, 545\u2013551 (2008).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio201313_CR75","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/CIRCULATIONAHA.105.575977","volume":"113","author":"J Mehilli","year":"2006","unstructured":"Mehilli, J. et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113, 273\u2013279 (2006).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR76","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jacc.2011.12.009","volume":"59","author":"D Carri\u00e9","year":"2012","unstructured":"Carri\u00e9, D. et al. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions. J. Am. Coll. Cardiol. 59, 1371\u20131376 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR77","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/eurheartj\/ehn253","volume":"29","author":"J Mehilli","year":"2008","unstructured":"Mehilli, J. et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur. Heart J. 29, 1975\u20131982 (2008).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201313_CR78","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1136\/hrt.2009.172379","volume":"95","author":"RA Byrne","year":"2009","unstructured":"Byrne, R. A. et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 95, 1489\u20131494 (2009).","journal-title":"Heart"},{"key":"BFnrcardio201313_CR79","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrcardio201313_CR80","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.111.026732","volume":"124","author":"S Massberg","year":"2011","unstructured":"Massberg, S. et al. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the intracoronary stenting and angiographic results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents (ISAR-TEST 5) trial. Circulation 124, 624\u2013632 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR81","unstructured":"Wilcox, J. Progress with a hollow-curve rapamycin filled stent (Medtronic). Presented at 24th Transcather Cardiovascular Therapeutics 2012."},{"key":"BFnrcardio201313_CR82","unstructured":"Seth, A. Nanoparticle based stents\u2014FOCUS np (Envision Scientific) program update. Presented at 24th Transcather Cardiovascular Therapeutics 2012."},{"key":"BFnrcardio201313_CR83","unstructured":"Cannon, L. Two-year outcomes from the PERSEUS randomised trial of the paclitaxel-eluting platinum chromium stent versus palitaxel-eluting stainless steel. Presented at 23rd Transcatheter Cardiovascular Therapeutics 2011."},{"key":"BFnrcardio201313_CR84","doi-asserted-by":"crossref","unstructured":"Stone, G. Two-year results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS\/XIENCE V Everolimus-eluting stents in de novo coronary artery lesions. Presented at the ACC Scientific Sessions 2012.","DOI":"10.1016\/S0735-1097(12)60324-6"},{"key":"BFnrcardio201313_CR85","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jacc.2008.12.012","volume":"53","author":"S Verheye","year":"2009","unstructured":"Verheye, S. et al. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. J. Am. Coll. Cardiol. 53, 1031\u20131039 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR86","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jcin.2009.11.014","volume":"3","author":"D Chami\u00e9","year":"2010","unstructured":"Chami\u00e9, D. et al. Serial angiography and intravascular ultrasound: results of the SISC Registry (Stents In Small Coronaries). JACC Cardiovasc. Interv. 3, 191\u2013202 (2010).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio201313_CR87","doi-asserted-by":"crossref","first-page":"16b","DOI":"10.1093\/eurheartj\/ehr384","volume":"33","author":"PW Serruys","year":"2012","unstructured":"Serruys, P. W., Garcia-Garcia, H. M. & Onuma, Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur. Heart J. 33, 16b\u201325b (2012).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201313_CR88","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1161\/01.CIR.102.4.371","volume":"102","author":"A Colombo","year":"2000","unstructured":"Colombo, A. & Karvouni, E. Biodegradable stents: \u201cfulfilling the mission and stepping away\u201d. Circulation 102, 371\u2013373 (2000).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR89","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(07)60853-8","volume":"369","author":"R Erbel","year":"2007","unstructured":"Erbel, R. et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369, 1869\u20131875 (2007).","journal-title":"Lancet"},{"key":"BFnrcardio201313_CR90","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.jacc.2008.08.024","volume":"52","author":"S Tanimoto","year":"2008","unstructured":"Tanimoto, S. et al. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J. Am. Coll. Cardiol. 52, 1616\u20131620 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR91","unstructured":"Grube, E. Bioabsorbable stent. The Boston Scientific and REVA technology. Presented at EuroPCR 2009."},{"key":"BFnrcardio201313_CR92","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0140-6736(08)60415-8","volume":"371","author":"JA Ormiston","year":"2008","unstructured":"Ormiston, J. A. et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371, 899\u2013907 (2008).","journal-title":"Lancet"},{"key":"BFnrcardio201313_CR93","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0140-6736(09)60325-1","volume":"373","author":"PW Serruys","year":"2009","unstructured":"Serruys, P. W. et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373, 897\u2013910 (2009).","journal-title":"Lancet"},{"key":"BFnrcardio201313_CR94","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1161\/CIRCULATIONAHA.110.970772","volume":"122","author":"PW Serruys","year":"2010","unstructured":"Serruys, P. W. et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 122, 2301\u20132312 (2010).","journal-title":"Circulation"},{"key":"BFnrcardio201313_CR95","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCINTERVENTIONS.112.971549","volume":"5","author":"JA Ormiston","year":"2012","unstructured":"Ormiston, J. A. et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ. Cardiovasc. Interv. 5, 620\u2013632 (2012).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"BFnrcardio201313_CR96","first-page":"286","volume":"2","author":"PW Serruys","year":"2006","unstructured":"Serruys, P. W. et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2, 286\u2013294 (2006).","journal-title":"EuroIntervention"},{"key":"BFnrcardio201313_CR97","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.jacc.2011.05.050","volume":"58","author":"PW Serruys","year":"2011","unstructured":"Serruys, P. W. et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J. Am. Coll. Cardiol. 58, 1578\u20131588 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201313_CR98","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2012)."},{"key":"BFnrcardio201313_CR99","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2012)."},{"key":"BFnrcardio201313_CR100","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ahj.2012.08.010","volume":"164","author":"R Diletti","year":"2012","unstructured":"Diletti, R. et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am. Heart J. 164, 654\u2013663 (2012).","journal-title":"Am. Heart J."},{"key":"BFnrcardio201313_CR101","first-page":"145","volume-title":"Percutaneous Interventional Cardiovascular Medicine","author":"PW Serruys","year":"2012","unstructured":"Serruys, P. W. et al. in Percutaneous Interventional Cardiovascular Medicine Part III, Ch. 4 (Eds Eeckhout, E., Serruys, P. W., Wijns, W., Vahanian, A. & van Sambeek, M.) 145\u2013177 (Europa Edition Publishing, Paris, 2012)."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2013.13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2013.13","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2013.13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T06:07:46Z","timestamp":1714975666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2013.13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,19]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["BFnrcardio201313"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2013.13","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,19]]}}}